The new model, called BaseFold, enables more reliable 3D structure predictions for larger and more complex proteins and, according to the company, is “poised to greatly accelerate AI-based drug ...
The company finally unveiled the new system in September, outing it as OpenAI’s first “reasoning” model and renaming it “o1.” Much like the two-stage release of GPT-2, where a stripped ...
Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...